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 RA-responsive mononuclear cells are increased in IL-23-rich human GI-GvHD tissue 
and are associated with poor outcome 
 These cells have a GI-tropic IL-23R+ CD8 effector T-cell phenotype and are 






Gastrointestinal (GI) graft-versus-host disease (GvHD) is a major barrier in allogeneic 
hematopoietic stem-cell transplantation (AHST). The metabolite retinoic acid (RA) potentiates 
GI-GvHD in mice via alloreactive T-cells expressing the RA-receptor-alpha (RARα), but the 
role of RA-responsive cells in human GI-GvHD remains undefined. We therefore used 
conventional and novel sequential immunostaining and flow cytometry to scrutinize RA-
responsive T-cells in tissues and blood of AHST patients and characterize the impact of RA 
on human T-cell alloresponses.  Expression of RARα by human mononuclear cells was 
increased after RA exposure. RARαhi mononuclear cells were increased in GI-GvHD tissue, 
contained more cellular RA-binding proteins, localized with tissue damage and correlated with 
GvHD severity and mortality. Using a targeted candidate protein approach we predicted the 
phenotype of RA-responsive T-cells in the context of increased microenvironmental IL-23. 
Sequential immunostaining confirmed the presence of a population of RARhi CD8 T-cells 
with the predicted phenotype, co-expressing the effector T-cell transcription factor T-bet and 
the IL-23-specific receptor. These cells were increased in GI- but not skin-GvHD tissues and 
were also selectively expanded in GI-GvHD patient blood. Finally, functional approaches 
demonstrated RA predominantly increased alloreactive GI-tropic RARhi CD8 effector T-cells, 
including cells with the phenotype identified in vivo. IL-23-rich conditions potentiated this effect 
by selectively increasing 7 integrin expression on CD8 effector T-cells and reducing CD4 T-
cells with a regulatory cell phenotype. In conclusion we have identified a population of RA-
responsive effector T-cells with a distinctive phenotype which are selectively expanded in 





Acute graft-versus-host disease (GvHD) is mediated by alloreactive donor T-cells that 
recognize and destroy healthy recipient tissues and results in significant morbidity and 
mortality after allogeneic hematopoietic stem-cell transplantation (AHST).1-3  Acute GvHD can 
target the skin and liver, but patients with disease involving the gastrointestinal (GI) tract have 
the poorest outcome.4 Current strategies to prevent GI-GvHD lack specificity and available 
therapies are unsatisfactory and cause significant toxicity. Better understanding of the tissue-
specific pathways involved in the differentiation, expansion and migration of alloreactive donor 
T-cells which mediate GI-GvHD will permit better ways to prevent or treat this barrier to 
successful AHST.  
Retinoic acid (RA), a metabolite of vitamin A, is a ligand for the nuclear RA receptors (RAR) 
α, β and γ which dimerize with retinoid X receptors at RA-response element sites to recruit co-
activator proteins and promote gene transcription. The interaction of RA with RARα increases 
T-cell homing capacity to the GI-tract.5 In addition, RA has diverse effects on immune cells by 
influencing both antigen-presenting cell (APC) function and T-cell differentiation. RA-signaling 
in the presence of TGF-β promotes immune tolerance in vitro by increasing CD4 regulatory T-
cell numbers and reducing cytokine production by CD4 effector T-cells,6,7 and RA production 
by APC in GI-associated lymphoid tissue contributes to maintenance of oral-antigen-
induced tolerance in vivo in steady-state conditions.8 However RA has also been shown to be 
essential for effector T-cell lineage stability,9 and in pro-inflammatory conditions RA increases 
CD4 Th1 and Th17 effector T-cell responses10 and potentiates CD8 effector T-cell 
differentiation.11,12 Thus the immune effects of RA are context-dependent, contributing to 
maintenance of tolerance in steady-state conditions but promoting effector T-cell responses 
in inflammatory microenvironments. 
Recent AHST studies in mice have shown that vitamin A-deficient diets reduce GI-GvHD,13 
and that RARα signaling in allogeneic donor T-cells potentiates GI-GvHD by increasing T-cell 
GI migration and also by modifying T-cell differentiation.14,15 Furthermore, there is emerging 
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evidence that RA-dependent T-cell differentiation may be influenced by cytokines which are 
increased in GI-GVHD, including IL-23 which reduces RA-induced expansion of CD4 
regulatory T-cells in other contexts,16 and IL-33 which enhances RA-signaling in CD4 T-cells.17 
Thus RA and cytokines that influence the impact of RA on T-cell differentiation could represent 
important new therapeutic targets to prevent or treat GI-GvHD. However, the impact of RA at 
a tissue level in human GI-GvHD is currently unknown. We therefore combined analysis of 
tissue biopsies and peripheral blood from AHST patients and in vitro modelling to investigate 




Materials and Methods 
 
Ethics approval  
The study was approved by the London Research Ethical Committee (05/Q0605/140 and 
06/Q0604/110) and conducted in accordance with the Declaration of Helsinki. Blood and 
tissue samples were obtained after signed informed consent from patients. 
 
Patients and biopsies 
Biopsies were performed for investigation of classical or late-onset acute GvHD in 54 AHST 
patients with hematologic malignancies or bone marrow failure (n=35 male, n=19 female, 
median age 51 years, range 20-66). Patients underwent granulocyte-colony-stimulating factor-
mobilized peripheral blood stem-cell transplantation from HLA-matched (n=50, 93%) or single-
antigen mismatched (n=4, 7%), related (n=20, 37%) or unrelated (n=34, 63%) donors using 
mostly fludarabine-based reduced-intensity conditioning (n=49, 91%), Table 1. All patients 
received uniform pharmacological immunoprophylaxis with short methotrexate and calcineurin 
inhibition weaned at D+90 in the absence of GvHD. 118 formalin-fixed paraffin-embedded 
biopsies (107 GI and 11 skin) from AHST patients performed prior to initiation of steroid 
therapy were studied and an additional 8 GI-biopsies from healthy controls with normal 
colonoscopies, Supplementary Figures 1 and 2 and Supplementary Table 1. Biopsies 
were independently reviewed by an expert histopathologist (MC) and histological GvHD 
confirmed using standard criteria.18 Clinical organ-specific acute GvHD staging at time of 
biopsy used modified Glucksberg criteria.19 Steroid-refractoriness was defined as no 
improvement after 14 days of 1-2mg/kg of prednisolone/equivalent. Peripheral blood CD3 T-
cell donor chimerism was assessed at the time of first biopsy by variable number tandem 




Conventional immunohistochemistry (IHC)  
Appropriate negative and positive healthy tissue controls based on published expression 
patterns were used to optimize antibody staining, Supplementary Figure 4. Images were 
captured using an Olympus Ariol microscope and Ariol automated image analysis (Genetix, 
San Jose, CA) was used to identify and enumerate mononuclear cells based on hematoxylin 
nuclear counterstaining characteristics. Antibody staining was digitized, the mean intensity 
calculated from number of pixels/mononuclear cell. Cells were considered positive if intensity 
was equivalent to cells in positive controls and counted automatically using the Ariol system. 
RARα antibody staining (rabbit polyclonal, 1:4000, Santa Cruz, Dallas TX) and image analysis 
was titrated to identify only mononuclear cells with high RARα expression. We used two 
regional approaches to RARαhi mononuclear cell enumeration; first we enumerated RARαhi 
mononuclear cells in the whole biopsy, excluding epithelial areas which were diffusely positive 
for RARα making identification of the small numbers of intraepithelial RARαhi mononuclear 
cells impossible. We also enumerated RARαhi mononuclear cells in sub-crypt regions adjacent 
to basal crypts where GvHD-related epithelial stem-cell damage occurs, Supplementary 
Figure 5. Further technical details of antibody staining are detailed in Supplementary 
Methods and Supplementary Table 2. 
 
Sequential immunostaining 
Sequential immunostaining, stripping and re-probing on the same formalin-fixed paraffin-
embedded biopsies was utilized to determine cellular co-expression of multiple markers.20 
After antigen retrieval, slides were stained with primary antibody, secondary antibody and VIP 
chromogen (as DAB could not be adequately stripped) and imaged before stripping by 
pressure-cooking and subsequent re-probing with the next antibody. Adequate stripping of 
primary antibodies was ensured by re-staining with secondary antibody and chromogen. 
Pannoramic Viewer v1.15.4 (3DHistech Ltd, Budapest, Hungary) was used to image cells. 
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Cells expressing high levels of staining were identified manually by the operator. To determine 
co-expression patterns of individual cells, each mononuclear cell within a minimum of 3 sub-
crypt regions/biopsy was electronically marked and cellular expression of sequential 
immunostains was recorded, Supplementary Figure 6.  The absolute number/unit area and 
proportion of mononuclear cells (minimum 200/biopsy) with each distinct expression pattern 
was collated. SPICE software version 5.3 (National Institute of Allergy and Infectious Disease) 
was used to depict frequencies of sub-populations of CD8 T-cells based on co-expression 
patterns of other molecules.  
 
Patient blood samples, flow cytometry and cluster analysis 
Flow cytometry used directly-conjugated antibodies, Supplementary Table 3, and viability 
dies to exclude dead cells. Analysis was performed using FlowJo software version 10 (LLC, 




Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation 
from healthy blood donor filters or patient samples thirty days after AHST and labelled with a 
cell proliferation trackers CFSE (Invitrogen) or Cell Trace Violet (Invitrogen, Waltham MA). 
Labelled responders were co-cultured with equal numbers of irradiated HLA-mismatched 
allogeneic stimulator PBMC with all-trans RA (100mM-1µM, Sigma-Aldrich, St Louis MO), 
lipopolysaccharide (LPS, 1g/ml, Sigma-Aldrich), human recombinant IL-23 (10ng/ml, 
Biolegend, San Diego CA) or vehicle controls in RPMI containing 10% FBS (Gibco, 
Gaithersburg, MD), 500iu penicillin and 0.5mg/ml streptomycin (Sigma-Aldrich). For some 
experiments the RARα-specific inhibitor ER-50891 (Santa Cruz) was added.  Responder T-




Two-tailed unpaired or paired tests were used to compare 2 groups as appropriate. Non-
parametric tests were used for non-normally distributed datasets. Comparison of multiple 
groups used unpaired/paired ANOVA (equal groups) or mixed effects models (unequal 
groups) with post-test correction. Cumulative incidence of GI-GVHD-related mortality was 
calculated with non-GvHD-related mortality and disease relapse as competing risks. Statistical 
analysis was performed using Prism version 5.0 (Graphpad, San Diego CA) and STATA 
version 13 (Statacorp, College Station, TX). 
 
Supplementary methods contain further detail of experimental and analytical techniques.  
 









RA-responsive mononuclear cells are increased in areas of GI-GvHD tissue damage  
As cellular RA cannot be measured in fixed tissue, and prior studies have shown RA exposure 
increases RARα mRNA in antigen-stimulated T-cells,24,25 we reasoned that cellular RARα 
expression could be used to identify RA-responsive cells. This was supported by initial 
observations that RARα protein expression was increased in PBMC by RA exposure during 
in vitro allostimulation, Figure 1A-B. We therefore developed an approach using conventional 
IHC to identify RA-responsive mononuclear cells with high RARα expression, Figure 1C, to 
scrutinize GI-biopsies from AHST patients with suspected GI-GvHD. Using this approach, 
RARαhi cells represented a median of 17% (range 2-61%) of mononuclear cells in the entire 
non-epithelial area of GI-biopsies, and correlated with cells expressing cellular RA-binding 
proteins 1 and 2 (CRABPI/II) which reflect cellular RA content and deliver RA to nuclear 
RARs26-28, Figure 1D. Regional analysis demonstrated significant enrichment of RARαhi cells 
in sub-crypt regions adjacent to areas of epithelial stem cell damage in GI-GvHD, Figure 1E-
F. 
We next compared numbers of RARαhi mononuclear cells in GI-biopsies with and without 
histological GvHD. Sub-crypt RARαhi cell numbers were significantly higher in biopsies with 
histological GvHD than in biopsies from AHST patients without histological GvHD or from 
healthy controls, Figure 1G-H. Total CRABPI/II was also significantly increased in sub-crypt 
regions of GI-biopsies with histological GvHD, consistent with local enrichment of cellular RA, 
Supplementary Figure 7. Sub-crypt RARαhi cell number had an optimal sensitivity and 
specificity of 77% and 91% respectively for presence of histological GvHD, with superior 
receiver-operator curve characteristics than RARαhi staining intensity or number of CRABPI/II+ 
cells, Figure 1I.  Importantly, sub-crypt RARαhi mononuclear cells were significantly increased 
in biopsies with histological GvHD from both the upper and the lower GI tract Figure 1J, but 
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were not significantly different in biopsies grouped by patient, donor or other clinical factors 
including time to biopsy Table 2.  
 
RARhi mononuclear cell numbers are associated with severity, response to treatment 
mortality of GI-GvHD 
Sub-crypt RARαhi cell numbers were significantly higher in patients with severe GI-GvHD 
(clinical stage 3-4) than in patients without GI-GvHD although RARαhi cells numbers did not 
differentiate patients with non-severe (stage 1-2) GI-GvHD. However, when this analysis was 
restricted to lower GI-biopsies, RARαhi cell numbers differentiated between patients with no 
GvHD, non-severe and severe GI-GvHD. Similarly, numbers of sub-crypt RARαhi cells were 
significantly higher in lower GI biopsies from patients who were subsequently refractory to 
steroid therapy. Finally, we examined the association of sub-crypt RARαhi cells with cumulative 
incidence (CI) of death attributable to GI-GvHD. We divided the patient cohort into tertiles 
according to sub-crypt RARαhi mononuclear cell numbers. The CI of GI-GvHD-related death 
was significantly greater in patients with higher numbers of sub-crypt RARαhi cells (76%, 32% 
and 10% in the first, second and third tertiles respectively, p= 0.002, Gray’s Test). 
Supplementary Figure 8. Taken together these data support an important role for RA-
responsive mononuclear cells in human GI-GvHD.  
 
A targeted candidate protein approach identifies a predicted phenotype of RA-
responsive cells in the context of increased microenvironmental IL-23 
In view of these findings we next used conventional IHC to quantify T-cell lineage markers, 
transcription factors, and the cytokines IL-23 and IL-33 and their receptors in the same biopsy 
cohort to predict the likely phenotype of RA-responsive cells, Figure 2A. Including both upper 
and lower GI-biopsies, numbers of CD8 T-cells in sub-crypt regions were significantly 
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increased and CD4 T-cell numbers significantly decreased in biopsies with histological GvHD, 
Figure 2B. 
Sub-crypt mononuclear cells expressing T-bet, a Th1/Tc1 effector T-cell transcription factor 
implicated in the pathogenesis of acute GvHD,29 and cells expressing the regulatory T-cell 
transcription factor FOXP3 were significantly increased in biopsies with histological GvHD, 
whereas there was no significant change in cells expressing the Th17/Tc17 transcription factor 
ROR-γt.30 In addition, cells expressing the IL-23p19 heterodimeric subunit of IL-23 
(subsequently termed IL-23) and cells expressing the IL-23-receptor (R) were both 
significantly increased in biopsies with histological GvHD whereas cells expressing IL-33 and 
the IL-33R were not, Figure 2C-D. These findings persisted when analyses were restricted to 
either upper or lower GI-biopsies, Supplementary Figure 9. Importantly, in addition to an 
increase in number of IL-23+ cells, the total cellular IL-23 was also significantly increased in 
sub-crypt regions of GI biopsies with histological GvHD, Figure 2E. Finally, correlation 
analyses demonstrated that despite some intersample variation, RARαhi cell numbers were 
modestly but significantly positively correlated with CD8 T-cells, cells expressing T-bet and 
cells expressing IL-23R, but not with numbers of cells expressing IL-23, Figure 2F and 
Supplementary Figure 10.  These data are consistent with expansion of a population of 
RARαhi CD8 T-cells co-expressing T-bet and IL-23R in GI-GvHD tissue in the context of 
increased microenvironmental IL-23.  
 
Sequential immunostaining confirms the presence of tissue-specific RARhi CD8 
effector T-cells co-expressing T-bet and IL-23R in GI-GvHD 
To further delineate the phenotype of RA-responsive T-cells in GI-biopsies we utilized a novel 
approach using sequential immunostaining, stripping and re-probing to measure expression 
of multiple markers on single cells, Figure 3A. Importantly, we validated the accuracy of this 
approach by demonstrating close correlation between frequencies of cells enumerated with 
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the sequential immunostaining pipeline and manual counting approach with frequencies of 
cells enumerated with single-stain IHC and automated counting, Figure 3B. 
We used sequential immunostaining to phenotype sub-crypt T-cells in 26 upper and lower GI-
biopsies from 22 AHST patients and 4 healthy controls. Initial analyses confirmed a significant 
increase in RARαhi CD8 T-cells in GI- biopsies with histological GvHD whereas there was no 
significant change in RARαhi CD4 T-cells. In addition, numbers of CD8 T-cells, but not CD4 T-
cells, expressing either T-bet or IL-23R were also significantly increased in biopsies with 
histological GvHD, Figures 4A-D. and Supplementary Figure 11 A-B.  In view of this we 
next enumerated 8 phenotypically distinct subpopulations of CD8 T-cells based on co-
expression patterns of RARα, T-bet and IL-23R. Importantly, the only CD8 T-cell sub-
population present in significantly increased proportions in GI-biopsies with histological GvHD 
co-expressed high levels of RARα, T-bet and IL-23R (triple positive cells) Figure 4E-F. This 
translated into a significant increase in the absolute number of triple positive CD8 T-cells in 
GI-biopsies with histological GvHD, Figure 4G, which was also seen when analysis was 
restricted to lower GI-biopsies, Supplementary Figure 11C-D.  
In order to asses if this novel population of triple positive CD8 effector T-cells was specific to 
GI tissues, we also performed sequential immunostaining staining on skin biopsies from 11 
AHST patients. There was no increase in the proportion of triple positive CD8 T-cells in skin 
biopsies with histological GvHD, Figure 4H. These findings support GI-tissue specificity of the 
triple positive CD8 T-cell effector population. 
Finally, as RA expands CD4 regulatory T-cells under some conditions,6,7 and we had found 
increased FOXP3+ mononuclear cells in GI-biopsies with histological GvHD, we also 
enumerated FOXP3+ CD4 T-cells using sequential immunostaining. Despite a reduction in 
overall RARαhi CD4 T-cells, RARαhi FOXP3+ CD4 T-cells were modestly increased in GI-
biopsies with histological GvHD, although these biopsies had 5-fold more RARαhi CD8 effector 
T-cells than RARαhi FOXP3+ CD4 T-cells, consistent with a net pro-inflammatory effect of RA-
responsive T-cells, Figure 4I. 
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RARαhi effector T-cells are also selectively expanded in the peripheral blood of GI-GvHD 
patients 
We next quantified RARαhi T-cell populations in peripheral blood of patients after AHST. 
Frequencies of triple positive CD8 T-cells were significantly increased in peripheral blood of 
GI-GvHD patients compared to skin GvHD patients, patients without GvHD or healthy controls 
Figure 5A-B.  In contrast, there was no significant increase in the frequency of RARαhi or triple 
positive CD4 T-cells in peripheral blood of GI-GvHD patients, Figure 5C. 
In order to assess GI-tissue selectivity of peripheral blood RARαhi CD8 effector T-cells, we 
also measured co-expression of molecules which confer GI-migratory capacity including the 
β7 subunit of the α4β7 integrin (as α4 is expressed on more than 90% of peripheral blood T-
cells) and CCR9. To contextualize these cells within broader immune reconstitution we 
performed unsupervised phenotypic clustering analysis on all live mononuclear cells. Using 
expression of 7 cell surface and intracellular molecules we identified 24 phenotypically distinct 
T-cell clusters, 12 of which were T-cell populations, Figure 5D-E. Only one (cluster 4) was 
present at significantly increased abundance in peripheral blood from GI- but not skin GvHD 
patients or healthy controls, which possessed the triple positive phenotype, expressed both 7 
and CCR9, and was expanded to a median frequency of 10% of live mononuclear cells in GI-
GvHD patients, Figure 5F-H. 
 
The dominant effect of RA on human alloresponses is an increase in GI-tropic RARαhi 
CD8 effector T-cells  
In view of the selective expansion of RARαhi CD8 effector T-cells we had demonstrated in both 
GI tissue and blood of GI-GvHD patients, we used allogeneic healthy donor PBMC co-cultures 
to investigate the impact of exogenous (all trans) RA on human T-cell alloresponses.  
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At lower doses of RA alloproliferation of both CD8 and CD4 T-cells was preserved. However, 
at higher doses of RA alloproliferation of CD8 T-cells was not significantly impacted whereas 
CD4 T-cell alloproliferation was significantly reduced (median 30% reduction), Figure 6A.  
Predictably, RA increased expression of GI-tropic molecules on both alloproliferative CD8 and 
CD4 T-cells, with maximum upregulation at 1µm concentrations, Supplementary Figure 12. 
Notably RA at 1µM concentrations also significantly increased the proportion of 
alloproliferative CD8 T-cells expressing high levels of RARα, the activation marker CD25, and 
the effector cell transcription factor T-bet, Figure 6B. A similar increase in the proportion of 
activated alloproliferative CD8 T-cells expressing CD25 was seen with RA added at the 
beginning of co-culture or at later time points, consistent with a direct effect on alloreactive T-
cells rather than an effect on APC, and CD8 effector T-cells expressing T-bet were found 
predominantly within the RARαhi CD8 T-cell compartment after RA exposure, as were cells 
upregulating GI-tropic molecules, Supplementary Figure 13A-C.  Exogenous RA resulted in 
a 2-fold increase in alloproliferative CD8 T-cells with the triple positive phenotype we had 
identified in tissue and blood of patients with GI-GvHD and a 5-fold increase in triple positive 
CD8 T-cells expressing GI-homing molecules, which was effectively blocked by a specific 
inhibitor of the RARα receptor, Figure 6B, as was expansion of CD8 T-cells expressing each 
individual protein, Supplementary Figure 13D, demonstrating that the effect is mediated by 
RARα ligation..  
In contrast RA exposure did not increase the proportion of alloproliferative CD4 effector T-
cells expressing high levels of T-bet, but did increase the proportion co-expressing CD25 and 
FOXP3 reflecting an increase in cells with a CD25hiFOXP3+ regulatory T-cell phenotype, 
Supplementary Figure 13E.  However, RA exposure resulted in significantly larger increases 
in alloproliferative CD8 effector T-cells than in CD4 FOXP3+ cells, consistent with a net pro-




Importantly, RA exposure induced similar phenotypic changes in alloproliferative T-cells in 
peripheral blood samples from AHST patients, Supplementary Figure 13 F-G.  
 
IL-23-rich conditions potentiate selective expansion of RA-responsive GI-tropic 
alloreactive CD8 effector T-cells  
As we had found IL-23+ mononuclear cells and RARαhi CD8 effector T-cells expressing the IL-
23R were both increased in GI-GvHD tissues we next sought to determine the impact of the 
combination of IL-23 and RA on human T-cell alloresponses. Increased frequencies of RARαhi 
CD8 effector T-cells were maintained with IL-23 and RA during allostimulation, but not 
significantly higher than with RA alone, Figure 6D and Supplementary Figure 14A-D. In 
contrast, the combination of RA and IL-23 resulted in significantly more alloproliferative CD8 
T-cells expressing the β7 integrin subunit and co-expressing both the α4 and β7 integrin 
subunits than RA or IL-23 alone, an effect that was not seen in alloproliferative CD4 T-cells, 
Figure 6 D-E and Supplementary Figure 14E-G. The increased expression of β7 induced by 
IL-23 and RA was largely restricted to RARαhi CD8 T-cells, resulting in a significant increase 
in β7 expression on CD8 effector T-cells with the triple positive phenotype identified in vivo, 
Supplementary Figure 14H. Importantly, IL-23 also significantly reduced RA-induced 
expansion of FOXP3+ CD4 T-cells, Supplementary Figure 14I, increasing the ratio of CD8 
effectors to FOXP3+ CD4 T-cells within the alloproliferative compartment, Figure 6F. 
Finally, in order to assess the impact of wider IL-23-rich pro-inflammatory environments on 
RA-responsive T-cell alloresponses we examined the effect of lipopolysaccharide (LPS), 
which is increased in GI tissue after AHST, induces macrophages to release IL-23 and 
provides multiple additional pro-inflammatory signals.31 LPS alone did not significantly 
increase alloproliferative RA-responsive CD8 effector T-cells whereas RA and LPS 
significantly increased frequencies of alloproliferative CD8 effector T-cells including cells with 
a GI-tropic triple positive phenotype, Figure 6G. This larger expansion facilitated phenotypic 
cluster analysis we had used in patient blood samples, Figure 6H-I. A single cluster of 
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alloproliferative CD8 effector T-cells was present at significantly higher frequency after RA and 
LPS exposure with a triple positive GI-tropic phenotype similar to that identified in peripheral 
blood of GI-GvHD patients. Notably this cluster had bright expression of β7 consistent with the 
effect we had identified in vitro with IL-23 and RA, Figure 6J-L.  
Taken together these data are consistent with IL-23 increasing GI-recruitment and/or retention 
of RA-responsive alloreactive CD8 effector T-cells and also limiting RA-induced expansion of 






In this study we show that RA-responsive T-cells are selectively increased at sites of GI-GvHD 
tissue damage in humans in the context of increased IL-23, and correlate with disease severity 
and mortality. Furthermore, we characterized these cells as predominantly CD8 effector T-
cells expressing high levels of RAR, T-bet and IL-23R. Our functional experiments confirm 
the dominant effect of RA on human T-cell alloresponses is to increase GI-tropic CD8 effector 
T-cells and is potentiated in IL-23-rich environments. Selectively targeting of this RA-
responsive CD8 effector T-cell population could provide a new strategy to prevent or treat GI-
GvHD.  
We studied patient biopsies from both the upper and lower GI-tract although most patients 
had biopsies from either just the lower GI-tract or from both sites. Although studies have shown 
that lower GI-GvHD has a more significant impact than upper GI-GVHD on GvHD-related 
mortality,32 upper GI pathology may increase lower GI-GvHD symptoms.33 Importantly, 
although numbers of RA-responsive cells in lower GI-biopsies were more closely associated 
with clinical severity of GI-GvHD than numbers in upper GI-biopsies, we found an increase in 
RA-responsive cells in both upper and lower GI-biopsies supporting a pathogenic role for RA-
responsive cells throughout the GI-tract.  
Intriguingly, several GI-biopsies without histological GvHD had evidence of alternative 
infective/inflammatory processes despite low levels of RA-responsive cells. However, the role 
of RA-responsive cells in AHST patients with CMV colitis, which can occur after post-
transplant and were not included in our study, will be important to further assess the specificity 
of these cells.  
To our knowledge no prior studies have examined the role of RA at a tissue level in human 
GI-GvHD, although multiple animal studies have shown vitamin A depletion, which reduces 
tissue RA levels, selectively reduces GI-GvHD.34,35 Intriguingly, a recent study in pediatric 
transplant recipients found GI-GvHD was associated with low plasma vitamin A levels. 36 
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Although we did not measure the plasma Vitamin A levels in our patients, but we show RA-
responsive effector T-cells and levels of RA-binding proteins (which are proportional to cellular 
RA content) were increased in GI-GvHD tissues. The precise relationship between plasma 
vitamin A levels and cellular RA levels in GI tissue remains to be determined, but our current 
findings highlight the importance of scrutinizing the GI-microenvironment where metabolite 
concentrations may be regionally concentrated.  
Our findings are consistent with recent murine studies that show GI-GvHD is mediated by RA-
responsive T-cells with increased RARα expression.14,15 In contrast to the findings in mice, 
despite RA upregulating GI-tropic molecules on alloproliferative CD8 and CD4 cells, we found 
only increases in RARαhi CD8 effector cells in GI-GvHD biopsies. One explanation for this may 
have been the selective reduction in CD4 alloproliferation we observed after in vitro RA 
exposure, potentially reflecting differential RA-response element utilization in murine and 
human T-cells. However, in common with these murine studies we found larger increases in 
RA-responsive effector T-cells were accompanied by smaller increases in CD4 T-cells with a 
regulatory phenotype in GI-GvHD tissue and after in vitro allostimulation in the presence of 
RA. This qualitatively distinct action of RA on human CD8 and CD4 T-cell alloresponses could 
represent a therapeutic opportunity if the two effects could be dissociated or selectively 
manipulated. 
Although most prior studies report T-cell infiltrates in human GI-GvHD tissue are 
predominantly CD8 T-cells,37,38 other studies show pathogenic CD4 T-cells play a role which 
may be licensed by microenvironmental factors other than RA.39-41 It is therefore likely that 
RA-responsive CD8 effector T-cells represent one of several distinct immune cell subsets 
contributing to the pathogenesis of GI-GvHD and the temporal distinction, interplay and 
functional dominance between RA-responsive CD8 effector T-cells and these other cell 
subsets remains to be determined.  
Although we did not directly demonstrate a causal role for IL-23 in selectively concentrating 
RA-responsive CD8 effector T-cells in vivo our findings suggest that IL-23, which modulates 
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T-cell responses to RA in other contexts may be one of the local factors influencing RA-
responsive T-cell alloresponses in the GI-microenvironment. Mononuclear cells expressing IL-
23 were increased in GI-GvHD tissues but did not correlate with RARαhi or CD8 T-cells, 
consistent with a trans effect on RA-responsive CD8 T-cells. IL-23 has been implicated in the 
pathogenesis of both murine and human GI-GvHD,42,43 and IL-23p19-specific blockade is in 
clinical use for autoimmune disease. However, as only half of RARαhi CD8 effector T-cells-in 
GI-GvHD tissues expressed the IL-23R, our results support targeting IL-23 as an adjunct but 
not an alternative to directly targeting RA-responsive CD8 effector T-cells. Furthermore, we 
cannot exclude the contribution of untested microenvironmental factors in licensing RA-
responsive CD8 effector T-cells, and the larger effect seen in vitro with LPS and RA compared 
to IL-23 and RA suggest that additional LPS-induced signals are also likely to contribute to the 
expansion of these pathogenic cells. 
 
The vast majority of biopsies in our study were from patients who had undergone AHST using 
reduced-intensity conditioning. Although this approach is commonly applied worldwide, we do 
not yet know if our findings can be generalized more widely to other full-intensity conditioning 
transplant platforms. Although it will be important to validate our findings after more intensive 
AHST conditioning including those containing total body irradiation, it is likely that expansion 
of RA-responsive effector T-cells also occurs in GI-GvHD in this setting as total body 
irradiation increases both LPS release and RA-signaling in the GI microenvironment in 
mice.44,45 
Further exploration of mechanisms by which RA directs alloreactive T-cell differentiation will 
be key for translation of our findings into strategies to prevent or treat GI-GvHD. Although 
RARα blockade is in development in other clinical contexts, this direct approach may not be 
optimal in the context of GI-GvHD as RA also has an important role in maintaining GI-mucosal 
integrity and Vitamin A deprivation in transplanted mice can redirect GvHD to other target 
organs.34,35. Identification of the individual RA-response elements in human alloreactive CD8 
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and CD4 T-cells could facilitate targeted therapeutic intervention, potentially uncoupling the 
impact of RA on CD8 effector T-cells and regulatory CD4 T-cells to promote tolerogenic T-cell 
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Table 1 Demographics, donor details and transplant conditioning for AHST patients 
whose biopsies were included in study  
Pt UPN Age 
(yrs) 
Diagnosis Conditioning Donor HLA match 
1 32 AML RIC (Flu/Mel*) Unrelated m/m 
2 65 CLL RIC (Flu/Bu) Unrelated matched 
3 36 CML RIC (Flu/Mel*) Related m/m 
4 50 AML RIC (Flu/Mel*) Unrelated m/m 
5 51 Myeloma RIC (Flu/Cy) Related matched 
6 62 FL (LPD) RIC (Flu/Cy) Unrelated matched 
7 62 MDS RIC (Flu/Cy) Unrelated matched 
8 47 Myeloma RIC (Flu/Cy) Unrelated matched 
9 51 ALL RIC (Flu/Cy) Unrelated matched 
10 53 NHL RIC (Flu/Cy) Unrelated matched 
11 32 MDS RIC (Flu/Cy) Unrelated matched 
12 51 MDS RIC (Flu/Cy) Unrelated matched 
13 44 AML RIC (Flu/Cy) Related matched 
14 31 ALL MA (Cy/TBI) Unrelated matched 
15 62 MDS RIC (Flu/Cy) Unrelated matched 
16 58 MCL (LPD) RIC (Flu/Cy) Related matched 
17 46 MF RIC (Flu/Cy) Related matched 
18 59 CLL (LPD) RIC (Flu/Bu) Unrelated matched 
19 41 FL (LPD) RIC (Flu/Cy) Unrelated matched 
20 35 CML MA (Bu/Cy) Related matched 
21 22 ALL MA (Bu/Cy) Unrelated matched 
22 53 AML RIC (Flu/Cy) Related matched 
23 57 FL (LPD) RIC (Flu/Cy) Unrelated matched 
24 30 ALL MA (Cy/TBI) Unrelated matched 
25 63 AML RIC (Flu/Cy) Related matched 
26 66 CLL (LPD) RIC (Flu/Bu) Unrelated matched 
27 64 MCL (LPD) RIC (Flu/Cy) Related matched 
28 42 HD (LPD) RIC (Beam*) Unrelated matched 
29 59 AML RIC (Flu/Cy) Related matched 
30 51 MDS RIC (Flu/Cy) Related matched 
31 43 ALL RIC (Flu/Cy) Related matched 
32 41 MDS RIC (Flu/Cy) Unrelated matched 
33 33 AA RIC (Flu/Cy/TBI*) Unrelated matched 
34 38 ALL RIC (Flu/Cy) Related matched 
35 39 CLL (LPD) RIC (Flu/Mel*) Unrelated m/m 
36 20 AML RIC (Flu/Cy) Unrelated matched 
37 43 MDS RIC (Flu/Cy) Unrelated matched 
38 38 ALL RIC (Flu/Cy) Unrelated matched 
39 56 MCL (LPD) RIC (Flu/Cy) Related matched 
40 53 MDS RIC (Flu/Cy) Unrelated matched 
41 41 MCL (LPD) RIC (Flu/Cy) Related matched 
42 51 AML RIC (Flu/Cy) Related matched 
43 60 CLL (LPD) RIC (Flu/Bu) Unrelated matched 
44 64 AML RIC (Flu/Cy) Related matched 
45 58 MDS RIC (Flu/Cy) Unrelated matched 
46 47 MDS RIC (Flu/Cy) Unrelated matched 
47 43 FL (LPD) RIC (Flu/Cy) Unrelated matched 





AML, acute myeloid leukemia; MDS, myelodysplasia; ALL, Acute lymphoblastic leukemia; 
MPD, myeloproliferative disorder; CLL, chronic lymphocytic leukemia; FL; Follicular 
lymphoma; MCL, Mantle cell lymphoma; CML, chronic myeloid leukemia; MF, myelofibrosis; 
LPD, lymphoproliferative disorder; AA, aplastic anemia; PBSC, peripheral blood stem cells; 
RIC, reduced intensity conditioning; Flu, Fludarabine; Cy, cyclophosphamide; Bu, Busulphan; 
Mel, Melphalan; Beam, BCNU, etoposide, Ara-C and Melphalan; MA, myeloablative; TBI, 
Total body irradiation; matched, HLA-matched (at A, B, C and DR); m/m, HLA mismatched at 
a single HLA-A or -C locus. * In vivo alemtuzumab 
  
49 64 MCL (LPD) RIC (Flu/Cy) Related matched 
50 55 CLL (LPD) RIC (Flu/Bu) Related matched 
51 48 MDS RIC (Flu/Cy) Unrelated matched 
52 57 AML RIC (Flu/Cy) Unrelated matched 
53 51 DLBCL (LPD) RIC (Flu/Cy) Unrelated matched 
54 52 AML RIC (Flu/Cy) Related matched 
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Table 2 Effect of clinical variables on GI biopsy sub-crypt RARαhi cell numbers 
 
Variable Group/number of patients Sub-crypt RARαhi cell 
number, mean (+/- SE) 
P* 
Recipient Age Below median, n=25 1387 +/- 248 .957 
Above Median, n=25 1407 +/- 280 
Recipient 
diagnosis 
Lymphoid malignancy, n=30 1404 +/- 244 .910 
Myeloid malignancy, n=20 1387 +/- 289 
Donor Family, n=19 1182 +/- 361 .420 
Unrelated, n=31 1522 +/- 204 
Conditioning RIC, n=46 1422 +/- 198 .450 
FIC, n=4 1112 +/- 426 
HLA match  
in GvHD vector 
Fully matched, n=46 1231 +/- 169 0.09 
Single antigen mismatch, n=4 3263 +/- 818 
T-cell depletion No, n=44 1276 +/- 175 .286 
Yes, n=6 2002 +/-  817 
Time to biopsy Before Day + 180 n=31 1574 +/- 246 .219 
After Day + 180 n=19 1117 +/- 272 
Histological GvHD  No, n=10 498 +/- 85 <0.001 
Yes, n=40 1599 +/- 213 
 
RIC, reduced intensity conditioning; FIC, full intensity conditioning; *unpaired t test without 






Figure 1 RA-responsive mononuclear cells are increased in areas adjacent to GI-GvHD 
tissue damage  
A RARα protein expression measured by flow cytometry in human peripheral blood 
mononuclear cells (PBMC) allostimulated in the absence or presence of exogenous RA. 
Example pseudodot plots are shown. Cells with high expression of RARα are shown in Region 
1 (R1).  B RARα protein expression in human PBMC allostimulated in the absence or presence 
of exogenous RA. Results depict 18 independent experiments. C Identification of RARαhi 
mononuclear cells in GI-biopsies using immunohistochemistry (IHC) staining for RARα (upper 
panel, brown) with hemotoxylin counterstaining (blue). After antigen retrieval, tissue was 
stained with rabbit anti-human RARα antibody (Santa Cruz, Clone F-9) for 40 min at RT. 
Sections were then stained using the Biogenex SuperSensitive™ Polymer-HRP IHC Kit and 
diaminobenzidine chromogen and counterstained with hematoxylin. Mononuclear cells were 
identified by size and nuclear staining characteristics (middle panel, blue dots) and RARα 
staining intensity was digitalized using the Ariol Olympus microscope and automated image 
analysis system (middle panel, red). A threshold of RARα staining intensity was set to identify 
cells with high RARα expression (lower panel, yellow dots). RARαhi mononuclear cells (lower 
panel, black arrows) were distinguished from mononuclear cells with lower expression of 
RARα (lower panel, green arrows). Scale bar is 10𝑢m. D Correlation between RARαhi 
mononuclear cell numbers and cellular RA binding protein (CRABP)I/II+ cell numbers in upper 
and lower GI-biopsies from ASHT patients. Solid and dotted lines denote linear regression 
and 95% confidence intervals respectively. r and p value is for Pearson correlation. E 
Representative GI-biopsy stained for RARα using conventional IHC and DAB chromogen.  
Sub-crypt regions are outlined in black and arrowed. Scale bar is 50𝑢m. F Enrichment of 
RARαhi mononuclear cell numbers enumerated using the Ariol automated system in sub-crypt 
regions of GI-biopsies. G Representative GI-biopsies stained for RARα using conventional 
IHC and DAB chromogen from healthy controls and AHST patients with and without 
histological GvHD. Scale bar is 50𝑢m. Black arrows depict mononuclear cells with high 
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expression of RARα  H RARαhi mononuclear cell numbers in sub-crypts of GI-biopsies with 
and without histological GvHD from AHST patients and from healthy controls. I Receiver-
Operator Curve characteristics for sub-crypt RARαhi cell numbers, RARαhi cell intensity and 
CRABPI/II+ cell numbers and the presence of histological GvHD. J RARαhi mononuclear cell 
numbers in sub-crypts of upper (left) and lower (right) GI-biopsies with and without histological 
GvHD. Horizontal lines on graphs depict medians. P values are for Mann Whitney tests for 
panels B, F, and ANOVA tests with correction for multiple comparisons for panels H and J.  
AUC, area under the curve. LR, likelihood ratio. **** p<0.0001 *** p<0.001 ** p<0.01, * p<0.05. 




Figure 2 A targeted candidate protein approach identifies a predicted phenotype of RA-
responsive cells in the context of increased microenvironmental IL-23 
A Mononuclear cell staining for T-cell lineage markers, transcription factors and the cytokines 
IL-23 and IL-33 and their receptors using conventional IHC in the same GI biopsy cohort. 
Scale bar is 100µm. Chromgen is DAB, positive cells are brown. Cells are counterstained with 
hematoxylin. B CD8 and CD4 T-cell numbers enumerated automatically using the Ariol system 
in sub-crypt regions of upper and lower GI-biopsies from AHST patients with and without 
histological GvHD. C Mononuclear cell numbers enumerated automatically using the Ariol 
system expressing T-cell transcription factors, cytokines and cytokine receptors in sub-crypt 
regions of upper and lower GI-biopsies from AHST patients with and without histological 
GvHD. D Volcano plot depicting fold change and statistical significance of RARαhi 
mononuclear cell numbers and cell numbers expressing T-cell lineage markers, transcription 
factors, cytokines and cytokine receptors in sub-crypt regions of upper and lower GI-biopsies 
from AHST patients with and without histological GvHD. E Total cellular IL-23 (calculated as 
the product of the number of IL-23+ mononuclear cells and the mean intensity of staining of 
cells for IL-23) in sub-crypt regions of upper and lower GI-biopsies from AHST patients with 
and without histological GvHD.  F Volcano plot depicting correlation co-efficients and statistical 
significance of numbers of RARαhi mononuclear cells and cells expressing T-cell lineage 
markers, transcription factors, cytokines and cytokine receptors in sub-crypt regions of upper 
and lower GI-biopsies from AHST patients. r and p values are for Pearson correlations. Cells 
expressing CD8, T-bet and IL-23R (circled) were significantly positively correlated with 
numbers of RARαhi mononuclear cells. Horizontal lines are medians. Other p values are for 




Figure 3 Sequential immunostaining of GI biopsies 
 
A Representative example of a GI-biopsy stained sequentially for RARα, IL-23R and T-bet 
using VIP chromogen and hematoxylin counterstain, with positive cells staining purple, and 
CD8 (using DAB chromogen, staining is brown). Sub-crypt regions are outlined in white. 
Cells with high and low/no expression of individual markers are indicated with red and black 
arrows respectively. Scale bar is 25µm. B Sequential immunostaining was validated by 
demonstrating a close correlation between mononuclear cell numbers in sequentially stained 
sections enumerated using manual counting and mononuclear cell numbers in the same 
sections stained using conventional single stain IHC and enumerated using automated cell 




Figure 4 Sequential immunostaining reveals an increase in tissue-specific RARhi 
CD8 effector T-cells co-expressing T-bet and IL-23R in GI-GvHD 
A-B RARαhi CD8 (A) and CD4 (B) T-cell numbers in sub-crypt regions of upper and lower GI-
biopsies from AHST patients with and without histological GvHD and lower GI-biopsies from 
healthy controls. C-D CD8 T-cell numbers co-expressing T-bet (C) or IL-23R (D) in sub-crypt 
regions of upper and lower GI-biopsies from AHST patients with and without histological GvHD 
and lower GI-biopsies from healthy controls. E SPICE plots depicting sub-populations of CD8 
T-cells in sub-crypt regions of GI-biopsies. Arcs represent median frequencies of CD8 T-cells 
expressing high RARα, T-bet or IL-23R. Slices represent median frequencies of CD8 T-cell 
subpopulations by co-expression patterns of RARα, T-bet and IL-23R. Results are shown for 
upper and lower GI-biopsies from 4 healthy controls and 22 AHST patients, 15 with and 7 
without histological GvHD.  F CD8 T-cell subpopulations expressed as percentage of total 
CD8 cells in sub-crypt regions of upper and lower GI-biopsies from 4 healthy controls (circles) 
and 22 AHST patients,15 with (diamonds) and 8 without (triangles) histological GvHD.  G 
Absolute numbers of CD8 T-cell subpopulations in sub-crypt regions of GI-biopsies. Color key 
is as shown in panel E. H SPICE plots depicting frequencies of sub-populations of CD8 T-cells 
in epidermis of skin biopsies from AHST patients. Pie arcs and slices as in E. Results are 
shown for biopsies from 11 AHST patients, 8 with and 3 without histological skin GvHD. I 
Absolute numbers of RARαhi CD4 T-cells co-expressing FOXP3 in sub-crypt regions of GI-
biopsies from 12 AHST patients and 4 healthy controls. Numbers of RARαhi T-bet+ CD8 
effector T-cells in GI-biopsies from AHST patients with histological GvHD are shown for 
comparison. Horizontal lines and adjacent numbers are medians. P values are for ANOVA 





Figure 5 RARαhi effector T-cells are also selectively expanded in the peripheral blood 
of GI-GvHD patients 
A Representative dot plots and histograms of RARα, IL-23R and T-bet expression on live CD8 
T-cells in peripheral blood of an AHST patient at onset of GI-GVHD and an AHST patient 
without GvHD from a similar time point. CD8 T-cells co-expressing high RARα and IL-23R in 
boxed region R1 (left) expressed high levels of T-bet (right), whereas RARαdim/neg and IL-
23Rneg CD8 T-cells in boxed region R2 expressed low levels of T-bet. B-C Percentage of live 
triple positive CD8 (B) and CD4 (C) T-cells (co-expressing high RARα, T-bet and IL-23R) from 
peripheral blood from healthy controls (n=4) and ASCT patients with GI- or skin-GvHD (n=7 
and 5 respectively) or without GvHD (n=8) at matched time points. D Unsupervised phenotypic 
clustering of live mononuclear cells from samples depicted in (B) displayed as Phenograph-
generated tSNE plots. Each cluster represents one of 24 phenotypically distinct T-cell subsets. 
E Heat map of relative expression levels of RARα, T-bet, IL-23R and the GI-tropic molecules 
β7 and CCR9 of distinct CD3 T-cell clusters displayed in panel D. F-G Volcano plots depicting 
fold change and statistical significance of abundance of distinct clusters within the peripheral 
blood live CD3 T-cell compartment from AHST patients with or without GI-GvHD (F) and with 
GI-or skin-GvHD (G). H Percentage of live mononuclear cells in cluster 4 in peripheral blood 
of AHST patients.  Horizontal lines are medians. P values are for ANOVA with post-test 
correction for multiple comparisons (B-C and H) or Mann Whitney tests (F-G) ** p<0.01, * 
p<0.05 trend (p<0.10) ns, not significant (p>0.10) 
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Figure 6 The dominant effect of RA on human alloresponses is to increase GI-tropic 
RARαhi CD8 effector T-cells and is potentiated in IL-23-rich conditions 
A Proportion of CD8 and CD4 T-cells proliferating after allostimulation in the absence or 
presence of RA (0.1 and 1 µM). Results are shown for 9 independent experiments.  B Heat 
map of percentage of alloproliferative CD8 and CD4 T-cells expressing GI-tropic molecules, 
high RARα, the activation marker CD25, the effector T-cell transcription factor T-bet and the 
CD4 regulatory T-cell transcription factor FOXP3 after allostimulation with/without exogenous 
RA (1µM). Results depict median values for between 6 and 25 independent experiments. C 
Fold-change in frequency of alloproliferative GI-tropic triple positive (TP) CD8 effector T-cells 
(co-expressing high RARα, T-bet, IL-23R) after allostimulation with/without exogenous RA (1 
µM) and the RARα-specific inhibitor ER-50891 (ER). Results depict 8 independent 
experiments. D Heat map of percentage of alloproliferative CD8 and CD4 T-cells the 
molecules depicted in (B) after allostimulation with exogenous RA (1µM) +/- IL-23. Results 
depict median values for 12-27 independent experiments except for α4β7 co-expression (3 
independent experiments). E Percentage of live alloproliferative CD8 T-cells expressing both 
α4 and β7 integrins allostimulated with/without exogenous RA (1µM) +/- IL-23. Results depict 
3-9 independent experiments. F Ratio of live alloproliferative cells with a CD8 effector T-cell 
(Teff):  CD4 regulatory T-cell (Treg) phenotype after allostimulation with exogenous RA (1µM) 
+/- IL-23. Results depict 24 independent experiments. G Fold-change in frequency of live 
alloproliferative GI-tropicP CD8 effector T-cells after allostimulation with/without exogenous 
RA (1µM) and/or lipopolysaccharide (LPS). Results depict 13 independent experiments. H 
Unsupervised phenotypic clustering of live PBMC after allostimulation with/without exogenous 
RA (1µM) and LPS displayed as Phenograph-generated tSNE plots. Clusters are derived from 
7 independent experiments. I Heat map of relative expression levels of RARα, T-bet, IL-23R 
and the GI-tropic molecules β7 and CCR9 of distinct cell trace violet (CTV)dim alloproliferative 
CD3 T-cell clusters. J Volcano plot depicting fold change and statistical significance of 
abundance of distinct T-cell clusters within live PBMC allostimulated with or without RA (1µM) 
39 
 
and LPS. Cluster colors are depicted in panel I.  K Percentage of live mononuclear cells in 
cluster 7 in PBMC allostimulated in the absence or presence of RA and LPS. L Phenotypic 
heat map for in vitro cluster 7 in human PBMC allostimulated with RA and LPS. The phenotype 
for cluster 4 seen in peripheral blood of GI-GvHD patients is also shown for comparison. CTV, 
cell trace violet. Horizontal lines are medians. P values are for Wilcoxon matched-pairs signed 
rank test (B, D, E, J and K) and ANOVA or mixed effects models with post-test correction (A, 
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